Facts for Prelims (FFP)
Source: The Print
Context: India’s Drug Controller General (DCGI) has granted market authorization for CAR-T (Chimeric Antigen Receptor-T) cell therapy developed by ImmunoACT, a spin-off company from IIT-Bombay.
- This ground-breaking treatment, known as NexCAR19, is now approved for use in cases of relapsed-refractory B-cell lymphoma and leukaemia.
- The therapy’s market authorization follows extensive scrutiny of data from phase 1 and 2 clinical trials by the Central Drugs Standards and Control Organisation (CDSCO).
